Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Sacherer, M; Kolesnik, E; von, Lewinski, F; Verheyen, N; Brandner, K; Wallner, M; Eaton, DM; Luha, O; Zweiker, R; von, Lewinski, D.
Thermic sealing in femoral catheterization: First experience with the Secure Device.
Cardiol J. 2019; 26(3):233-240
Doi: 10.5603/CJ.a2018.0035
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Sacherer Michael
- von Lewinski Dirk
- Co-Autor*innen der Med Uni Graz
- Kolesnik Ewald
- Verheyen Nicolas Dominik
- von Lewinski Friederike
- Wallner Markus
- Zweiker Robert
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Devices currently used to achieve hemostasis of the femoral artery following percutaneous cardiac catheterization are associated with vascular complications and remnants of artificial materials are retained at the puncture site. The Secure arterial closure Device induces hemostasis by utilizing thermal energy, which causes collagen shrinking and swelling. In comparison to established devices, it has the advantage of leaving no foreign material in the body following closing. This study was designed to evaluate the efficacy and safety of the Secure Device to close the puncture site following percutaneous cardiac catheterization. METHODS: The Secure Device was evaluated in a prospective non-randomized single-center trial with patients undergoing 6 F invasive cardiac procedures. A total of 67 patients were enrolled and the device was utilized in 63 patients. Fifty diagnostic and 13 interventional cases were evaluated. Femoral artery puncture closure was performed immediately after completion of the procedure. Time to hemostasis (TTH), time to ambulation (TTA) and data regarding short-term and 30-day clinical follow-up were recorded. RESULTS: Mean TTH was 4:30 ± 2:15 min in the overall observational group. A subpopulation of patients receiving anticoagulants had a TTH of 4:53 ± 1:43 min. There were two access site complications (hematoma > 5 cm). No major adverse events were identified during hospitalization or at the 30 day follow-up. CONCLUSIONS: The new Secure Device demonstrates that it is feasible in diagnostic and interventional cardiac catheterization. With respect to safety, the Secure Device was non-inferior to other closure devices as tested in the ISAR closure trial.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged - administration & dosage
- Austria - administration & dosage
- Cardiac Catheterization - administration & dosage
- Catheterization, Peripheral - adverse effects
- Equipment Design - administration & dosage
- Feasibility Studies - administration & dosage
- Female - administration & dosage
- Femoral Artery - diagnostic imaging
- Hemorrhage - etiology, prevention & control
- Hemostatic Techniques - adverse effects, instrumentation
- Humans - administration & dosage
- Male - administration & dosage
- Middle Aged - administration & dosage
- Prospective Studies - administration & dosage
- Punctures - administration & dosage
- Time Factors - administration & dosage
- Treatment Outcome - administration & dosage
- Find related publications in this database (Keywords)
- catheterization
- vascular closure device
- thermal vascular occlusion
- Secure Device System
- femoral vascular access